Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT

BMC Cancer. 2019 Jun 20;19(1):606. doi: 10.1186/s12885-019-5728-8.

Abstract

Background: The prognosis of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma is still dismal. There are no standard treatment strategies for these patients. Multidisciplinary team (MDT) approach is a good choice for making a high-quality decision. Generally, MDT will recommend these patients to receive preoperative chemotherapy or preoperative chemoradiation based on all kinds of treatment guidelines. However, the preferred preoperative treatment is still not established. In order to solve this problem, we carry out this randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma.

Methods: Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy. In the preoperative chemoradiation arm (Pre-CRT), patients receive two cycles of S-1 and oxaliplatin (SOX), chemoradiation, then followed by surgery and three more cycles of SOX chemotherapy. In the preoperative chemotherapy arm (Pre-CT), patients receive three cycles of SOX, following surgery three more cycles of SOX are given. The primary endpoint of this trial is to verify that preoperative chemoradiation could significantly improve the 3-year disease free survival (DFS) of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma compared to preoperative chemotherapy.

Discussion: The results from this trial will provide important information about whether preoperative chemoradiation could improve survival compared to preoperative chemotherapy among patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma.

Trial registration: ClinicalTrials.gov Identifier: NCT03013010. First posted January 6, 2017.

Keywords: Adjuvant chemotherapy; Esophagogastric junction adenocarcinoma; Gastrectomy; Gastric cancer; Preoperative Chemoradiation; Preoperative chemotherapy.

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / surgery
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / therapeutic use
  • Chemoradiotherapy, Adjuvant*
  • Chemotherapy, Adjuvant*
  • China
  • Disease-Free Survival
  • Drug Combinations
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / surgery
  • Esophagogastric Junction / pathology*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Oxaliplatin / therapeutic use
  • Oxonic Acid / therapeutic use
  • Prospective Studies
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / surgery
  • Tegafur / therapeutic use
  • Young Adult

Substances

  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • Oxaliplatin
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid

Supplementary concepts

  • Adenocarcinoma Of Esophagus

Associated data

  • ClinicalTrials.gov/NCT03013010